LHRH agonist treatment of breast cancer and gynecological malignancies: a review
- 31 July 1996
- journal article
- review article
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 67 (1) , 27-33
- https://doi.org/10.1016/0301-2115(96)02424-4
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Goserelin in Premenopausal Advanced Breast Cancer: Clinical and Endocrine Evaluation of Responsive PatientsOncology, 1994
- Endocrine treatment for breast cancers: Biological rationale and current progressThe Journal of Steroid Biochemistry and Molecular Biology, 1990
- A response in advanced post-menopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist — ZoladexCancer Letters, 1989
- Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.Journal of Clinical Oncology, 1989
- ZOLADEX als Depot GnRH-Agonist beim prämenopausalen metastasierten MammakarzinomArchiv für Gynäkologie, 1989
- Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630British Journal of Cancer, 1986
- The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancerBritish Journal of Cancer, 1986
- Treatment of Breast Cancer with Gonadotropin-Releasing HormoneEndocrine Reviews, 1986
- LHRH-Agonist treatment in clinical and experimental human breast cancerJournal of Steroid Biochemistry, 1985
- TREATMENT WITH A LUTEINISING-HORMONE-RELEASING-HORMONE ANALOGUE (BUSERELIN) IN PREMENOPAUSAL PATIENTS WITH METASTATIC BREAST CANCERThe Lancet, 1982